

LIST OF TABLES

<u>TABLE NO.</u>	<u>TABLE CAPTION</u>	<u>PAGE NO.</u>
CHAPTER 1		
Table 1.1	Milestones in the history of Tuberculosis	3
Table 1.2	Chemotherapy for the treatment of Active TB	8
Table 1.3	Categories of antituberculosis drugs	9
Table 1.4	Mechanism of action and resistance of anti-TB drugs	10-11
Chapter 2		
Table 2.1	The table summarizes all the plasmid vectors used as a part of the study.	41
Table 2.2	The table summarizes all the primers used for Polymerase Chain Reactions (PCR) in the present study.	41-42
Table 2.3	The table summarizes the components of the PCR reaction mixtures.	44
Table 2.4	The table summarizes the parameters for thermal cycling reactions in the PCR.	44
Table 2.5	The table summarizes the expected phenotypes of the different mutants and the wild type.	61
Chapter 3		
Table 3.1	List of primers used in the complementation study	73

LIST OF FIGURES

FIGURE NO.	FIGURE CAPTION	PAGE NO
CHAPTER 1		
Figure1.1	Percentage of new and relapse TB cases in 2016.	5
Figure 1.2	Cell wall structure of <i>Mycobacterium sp.</i>	12
Figure 1.3	The five ESX T7SS loci present in <i>M. tuberculosis</i>	16
Figure 1.4	A model for ESX-1 mediated secretion in Mycobacteria	17
CHAPTER 2		
Figure 2.1	A schematic representation of all the steps involved in the construction of the recombination cassette for the disruption of <i>eccD3</i> in <i>M. smegmatis</i> using <i>kan^r</i> (<i>aph</i>) gene.	43
Figure 2.2	A schematic representation of the PCRs used for genotypic verification of the <i>eccD3</i> deleted clone in <i>M. smegmatis</i>	49
Figure 2.3	Schematic representation of the <i>esx-3</i> loci from <i>M. tuberculosis</i> and <i>M. smegmatis</i>	50
Figure 2.4	Sequence alignment of MSMEG_0622 and Rv0290	51
Figure 2.5	0.8% agarose gel showing the results of PCR amplification of 1 kb upstream region of <i>eccD3</i> cloning in pGGEMT7f(+) vector	52
Figure 2.6	0.8% agarose gel showing the results of restriction digestion of the plasmids isolated from the putative clones.	52
Figure 2.7	Chromatogram of the upstream fragment of <i>eccD3</i> gene viewed in the Chromas software.	53

Figure 2.8	Sequence alignment of the upstream gene cloned in pGEMT7Zf(+) and <i>M. smegmatis</i> MSMEG_0622.	54
Figure 2.9	0.8% agarose gel showing the results of PCR amplification of 1kb region downstream of <i>eccD3</i> gene and cloning in pD3UP vector	55
Figure 2.10	1% agarose gel showing the results of insert specific digestions of pD3UPDN.	55
Figure 2.11	Chromatogram of the downstream fragment (MSMEG_0624) of <i>eccD3</i> gene cloned in pD3UP as viewed in the Chromas software	56
Figure 2.12	Sequence alignment of the downstream gene cloned in pD3UP and <i>M. smegmatis</i> MSMEG_0624	57
Figure 2.13	0.8 % agarose gel showing the cloning of <i>kan^r</i> in pD3UPDN vector	58
Figure 2.14	Vector map of pPR27, suicide vector	59
Figure 2.15	1% agarose gel showing the results of PCR amplification of 3.3 kb region from pD3UPDNkan corresponding to the recombination cassette and cloning in the pPR27 vector.	59
Figure 2.16	1% agarose gel showing the results of restriction digestion of putative clones of pD3UPDNkan	59
Figure 2.17	Strategies used to generate the <i>M. smegmatis</i> <i>eccD3</i> deletion mutant	60
Figure 2.18	Putative colonies being checked for kanamycin resistance at 39 ⁰ C in 7H9 media supplemented with 10% ADC, 15% sucrose, 0.2% glucose and kanamycin	61
Figure 2.19	Checking for gentamycin sensitivity of the	61

	same clones as in Figure 2.18	
Figure 2.20	0.8% agarose gel showing the products of PCR amplification with set 1 primers	62
Figure 2.21	0.8% agarose gel showing the products of PCR amplification with set 2 primers	63
Figure 2.22	0.8% agarose gel showing the products of PCR amplification with set 3 primers	63
 CHAPTER 3		
Figure 3.1	0.8% agarose gel showing the results of PCR amplification of 1428bp region of <i>eccD3</i>	75
Figure 3.2 [A]	Vector map of pMV261	75
Figure 3.2 [B]	0.8 % agarose gel showing the band shift of the rpMV261hyg plasmid	75
Figure 3.3	Sequence alignment of the <i>eccD3</i> gene cloned in pMV261hyg and <i>M. smegmatis</i> MSMEG_0623	76
Figure 3.4	1% agarose gel showing RNA isolated from the wild type mc ² 155, mutant, Ms0622 and the complemented strain Ms622/pEccD3	77
Figure 3.5	Expression profile of <i>eccD3</i> in Wild type (WT), Mutant (Ms0622), and Complement (Ms0622/pEccD3) detected by semi-quantitative RT-PCR	78
Figure 3.6	Expression profile of <i>mycP3</i> in Wild type (mc2155), Mutant (Ms0622), and Complement (Ms0622/pEccD3) detected by semi-quantitative RT-PCR	78-79
 CHAPTER 4		
Figure 4.1	Effect of <i>eccD3</i> deletion on colony morphology of (A) mc ² 155, wild type; (C) Ms06622, <i>eccD3</i>	91

	deleted mutant and (E) Ms06622/pEccD3, <i>eccD3</i> complemented strain	
Figure 4.2	Effect of <i>eccD3</i> deletion on formation of pellicle	92
Figure 4.3	Macroscopic spreading analysis on the surface of a motility agar plate	92
Figure 4.4	Effect of <i>eccD3</i> deletion on growth kinetics of the wild type <i>M. smegmatis</i> mc ² 155; <i>eccD3</i> mutant, Ms0622 and complemented strain Ms0622/pEccD3	93
Figure 4.5	Effect of <i>eccD3</i> deletion on biofilm formation.	94
Figure 4.6	Biofilm formation assayed in the wild type <i>M. smegmatis</i> , mc ² 155 in the presence of 0μM and 5μM iron in the biofilm growth media.	95
Figure 4.7	Growth of mycobacterial biofilm in presence of increasing concentration (0, 0.5, 1, 2 and 5μM) of iron	96
Figure 4.8	Increased sensitivity of the <i>eccD3</i> mutant to H ₂ O ₂	97
Figure 4.9	Sensitivity of the <i>eccD3</i> <i>M. smegmatis</i> mutant to various environmental stress	98
Figure 4.10	Effect of SDS treatment on bacterial survival	99
Figure 4.11	Deletion of <i>eccD3</i> in <i>M. smegmatis</i> results in decreased cell wall permeability	100
Figure 4.12	Antibiotic susceptibility of <i>eccD3</i> mutant by disk diffusion assays	101
CHAPTER 5		
Figure 5.1	Reactions involved in the FAS I system in the formation of precursor fatty acid (C ₂₀) for the FAS II system	117

Figure 5.2	Mycolic acid subspecies of <i>M. smegmatis</i>	118
Figure 5.3	Mycolic acid subspecies of <i>M. tuberculosis</i>	119
Figure 5.4	Confocal microscopy of the wild-type mc ² 155 and the <i>eccD3</i> deleted strain, Ms0622 of <i>M. smegmatis</i>	124
Figure 5.5	Scanning electron micrographs of the wild-type, mc ² 155; mutant Ms0622, and complemented strain, Ms0622/pEccD3	124
Figure 5.6	TLC analysis of mycolic acid methyl esters (MAMES) of the wild type mc ² 155 and the <i>eccD3</i> deleted Ms0622 strain of <i>M. smegmatis</i> .	125
Figure 5.7	Differential scanning calorimetry of (A) cell wall and (B) purified mycolic acids from Wild type <i>M. smegmatis</i> mc ² 155, and <i>eccD3</i> deleted strain, Ms0622.	126-127
Figure 5.8	GC of the isolated FAMES from the (A) wild type <i>M. smegmatis</i> mc ² 155 and (B) deleted <i>eccD3</i> <i>M. smegmatis</i> , Ms0622.	128
Figure 5.9	Pyrolytic cleavage of TMS derivatized mycolic acid methyl esters at C ₂ -C ₃ and C ₃ -C ₄ atom yields [B] ⁺ ion and the α-unit	129
Figure 5.10	GC of α unit of the isolated α subspecies of mycolic acid from the wild type <i>M. smegmatis</i> mc ² 155.	130
Figure 5.11	Mass spectra of trimethylsilyl ether derivatives of α-unit of the isolated α subspecies of mycolic acid methyl esters from the wild type <i>M. smegmatis</i> mc ² 155	130-131
Figure 5.12	GC of the isolated α subspecies of mycolic acid from the <i>eccD3</i> deleted <i>M. smegmatis</i> , Ms0622.	131
Figure 5.13	Mass spectra of trimethylsilyl ether derivatives	132

of α -unit of the isolated α subspecies of mycolic acid from the *eccD3* deleted *M. smegmatis*, Ms0622

- | | | |
|-------------|--|-----|
| Figure 5.14 | NMR spectra of the α mycolic acid of A) Wild type, mc ² 155 and B) <i>eccD3</i> mutant, Ms0622 | 134 |
| Figure 5.15 | NMR spectra of the epoxy mycolic acid of A) Wild type, mc ² 155 and B) <i>eccD3</i> mutant, Ms0622 | 135 |

⁰ C	Degree Celcius
μg	Microgram
μM	Micro Molar
¹ HNMR	Proton Nuclear Magnetic Resonance
A	Adenine
AIDS	Acquired immunodeficiency syndrome
BCG	Bacille of Calmette and Guerin
bp	Base pair
C	Cytosine
DMSO	Dimethyl sulfoxide
DSC	Density Scanning Calorimetry
ETH	Ethambutol
FAME	Fatty Acid Methyl Ester
FASI	Fatty Acid Synthase I
FASII	Fatty Acid Synthase II
G	Guanine
GC-MS	Gas Chromatography–Mass Spectrometry
H ₂ O ₂	Hydrogen peroxide
hr/s	Hour/s
HCl	Hydrochloric Acid

HIV	Human immunodeficiency virus
INH	Isoniazid
kDa	kilodalton
KH_2PO_4	Potassium Dihydrogen Phosphate
lit	Litre
M	Molar
<i>M</i>	<i>Mycobacterium</i>
mA	Milli ampere
mAGP	Mycolyl- arabinogalactane- peptidoglycan
MDR-TB	Multi Drug Resistant Tuberculosis
mg	Milligram
mins	Minutes
ml	Milliliter
mM	Milli Molar
Na_2HPO_4	Disodium Hydrogen Phosphate
NaOH	Sodium Hydroxide
OADC	Oleic Acid – Albumin- Dextrose- Catalyst
PBS	Phosphate Buffer Saline
RIF	Rifampicin
rpm	Revolution per minute

rRNA	Ribosomal Ribonucleic Acid
RT-PCR	Reverse transcriptase polymerase chain reaction
S	Svedberg Unit
SE	Standard Error
SEM	Scanning Electron Microscope
<i>Sp.</i>	Species
TB	Tuberculosis
TMS	Tri Methyl Silane
WHO	World Health Organization
XDR-TB	Extensively Drug Resistant Tuberculosis